Scalper1 News
Biotech Neurocrine Biosciences (NBIX) said Thursday that its drug for tardive dyskinesia had succeeded in a late-stage trial, sending its stock up sharply in early trading. Tardive dyskinesia is a syndrome that causes involuntary, repetitive movements, generally as a side effect of antipsychotic drugs. So the patients in Neurocrine’s trial, called Kinect 3, had severe psychiatric disorders along with their TD. Neurocrine said that patients who Scalper1 News
Scalper1 News